Zoetis Inc. $ZTS Shares Sold by Fifth Third Bancorp

Key Points

• Fifth Third Bancorp has reduced its holdings in Zoetis Inc. by 11.2%, now owning 170,777 shares valued at approximately $26.63 million.
• Zoetis reported earnings per share of $1.76 for the last quarter, exceeding expectations, and projected FY 2025 guidance at 6.300-6.400 EPS.
• Several analysts have downgraded Zoetis, while five maintain a Buy rating, with a consensus target price of $200.88.

Fifth Third Bancorp trimmed its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 11.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 170,777 shares of the company's stock after selling 21,645 shares during the quarter. Fifth Third Bancorp's holdings in Zoetis were worth $26,633,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Lindbrook Capital LLC lifted its holdings in shares of Zoetis by 1.8% in the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock valued at $612,000 after buying an additional 65 shares during the period. Secure Asset Management LLC raised its position in Zoetis by 2.9% in the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company's stock worth $382,000 after acquiring an additional 68 shares in the last quarter. Quotient Wealth Partners LLC lifted its holdings in Zoetis by 2.3% in the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock valued at $521,000 after acquiring an additional 72 shares during the last quarter. Broadway Wealth Solutions Inc. boosted its position in shares of Zoetis by 4.4% during the 1st quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock valued at $287,000 after purchasing an additional 73 shares in the last quarter. Finally, Menard Financial Group LLC boosted its position in shares of Zoetis by 3.8% during the 1st quarter. Menard Financial Group LLC now owns 2,032 shares of the company's stock valued at $305,000 after purchasing an additional 75 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

NYSE ZTS opened at $141.65 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $62.78 billion, a PE ratio of 24.38, a price-to-earnings-growth ratio of 2.29 and a beta of 0.89. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $197.51. The company has a 50 day moving average price of $150.63 and a two-hundred day moving average price of $156.07.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the company earned $1.56 earnings per share. The business's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Argus reaffirmed a "buy" rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Finally, Piper Sandler lifted their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Zoetis has a consensus rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.